Drug Trial Dynamics
The discussion delves into the high stakes of drug trials, particularly phase three studies, where the average success rate hovers around 50%. Insights reveal how the market often treats every drug as a coin toss, impacting company valuations significantly. By conducting thorough research, it's possible to identify drugs with a higher likelihood of success, potentially achieving consistent outperformance in investments.In this clip
From this podcast
Capital Allocators – Inside the Institutional Investment Industry
Andy Acker - Empty Rooms: Investing in Biotech at Janus Henderson (Capital Allocators, EP.274)
Related Questions